035610.Kq
The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and healthcare IT solutions.
Business. The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and healthcare IT solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and healthcare IT solutions.
The company maintains a strong liquidity position, with a current ratio of 5.25, indicating that it has more than five times the current assets to cover its current liabilities. Its cash and equivalents amount to KRW 22.7 billion, and it has a free cash flow of KRW 35.2 billion, which supports its operational flexibility and capacity for reinvestment. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, the company generates a return on equity (ROE) of 9.82% and a return on assets (ROA) of 5.57%, both of which are strong indicators of efficient asset utilization and profitability. These metrics are well above the typical thresholds for the healthcare equipment industry, suggesting that the company is outperforming its peers in terms of capital efficiency and earnings generation.
The company's revenue is primarily concentrated in its core medical equipment and technology segments, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to regional economic or regulatory risks, although the lack of disclosed geographic breakdown limits the ability to assess this risk in detail.
Looking ahead, the company is expected to maintain a stable growth trajectory, with no immediate signs of significant revenue acceleration or contraction. The capital expenditure for the period was negative at KRW 527.5 million, indicating a reduction in investment in physical assets, which may reflect a focus on optimizing existing infrastructure or reallocating capital to other strategic initiatives.
The risk assessment indicates a low probability of liquidity or dilution issues in the near term. The company has a low debt-to-equity ratio and a strong cash position, which reduces the likelihood of needing to raise additional capital through equity issuance. Additionally, no immediate filing-based flags for dilution or liquidity were detected, suggesting that the company is in a stable financial position.
Recent financial filings and transcripts do not indicate any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company appears to be maintaining a steady course, with no major disruptions or announcements reported in the latest available data.
- The company has a strong liquidity position with a current ratio of 5.25 and a free cash flow of KRW 35.2 billion.
- It generates a high return on equity (9.82%) and return on assets (5.57%), outperforming typical industry benchmarks.
- The company maintains a conservative capital structure with a debt-to-equity ratio of 0.01.
- No immediate liquidity or dilution risks are identified, and the company appears to be in a stable financial position.
- The company's revenue is concentrated in its core medical equipment and technology segments, with no significant geographic diversification disclosed.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 035610.KQ Market data — financials · 2026-05-26